This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.64% per year. These returns cover a period from January 1, 1988 through August 4, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
biotechs: Archive
BioCryst Pharmaceuticals Before Q2 Earnings: How to Play the Stock
by Ahan Chakraborty
BCRX gears up for Q2 results with Orladeyo growth in focus, but 2025 EPS forecasts dip as investors eye pipeline progress.
BCRXNegative Net Change IONSNegative Net Change NTLANo Net Change
biotechnology biotechs earnings-preview medical pharmaceuticals
TEVA Q2 Earnings Beat, Revenues Miss on Lower Generics Sales
by Zacks Equity Research
TEVA tops Q2 earnings expectations as branded drugs shine, but revenues slip on weak generics and Japan exit.
JNJNegative Net Change TEVAPositive Net Change ABBVNegative Net Change
biotechnology biotechs earnings medical pharmaceuticals
AbbVie Beats on Q2 Earnings & Sales, Stock Up on Raised '25 EPS View
by Zacks Equity Research
ABBV tops Q2 forecasts and lifts 2025 EPS outlook as Rinvoq and Skyrizi drive growth amid Humira's decline.
RHHBYNegative Net Change JNJNegative Net Change ABBVNegative Net Change
biotechs earnings medical pharmaceuticals
Bristol Myers Beats on Q2 Earnings and Sales, Raises '25 Sales View
by Zacks Equity Research
BMY's Q2 EPS and revenues beat estimates, powered by strong Growth portfolio sales and a lesser than expected decline in Legacy portfolio sales.
BMYNegative Net Change PFENegative Net Change EXELPositive Net Change BNTXNegative Net Change
biotechnology biotechs earnings medical pharmaceuticals
Biogen's Q2 Earnings & Sales Beat, 2025 Outlook Raised, Stock Up
by Zacks Equity Research
BIIB posts Q2 earnings and sales beat, lifts 2025 outlook on new drug growth and displays resilient MS performance.
BIIBNegative Net Change RHHBYNegative Net Change SUPNNegative Net Change
biotechs
Bausch Health Stock Falls on Q2 Earnings Miss, Revenues Beat
by Zacks Equity Research
BHC stock falls 6.3% as Q2 earnings miss estimates despite stronger sales and growth in key segments like Salix and Solta Medical.
CRMDNegative Net Change BHCPositive Net Change ARVNNegative Net Change
biotechnology biotechs earnings medical pharmaceuticals
Amarin's Q2 Earnings & Revenues Trump Estimates, Stock Rises
by Zacks Equity Research
AMRN beats second-quarter estimates for earnings. Revenues rise year over year on strong licensing gains.
AMRNPositive Net Change CRMDNegative Net Change ARVNNegative Net Change IMCRNegative Net Change
biotechs earnings
Ionis Beats on Q2 Earnings & Sales, Stock Up 5% on Raised '25 Outlook
by Zacks Equity Research
Ionis crushes Q2 estimates with EPS of $0.86 and sales of $452 million, lifting its 2025 revenue forecast and sending shares up 5%.
AZNNegative Net Change NVSNegative Net Change BIIBNegative Net Change IONSNegative Net Change
biotechs earnings medical pharmaceuticals
GSK Beats on Q2 Earnings & Sales, Stock Gains on '25 Outlook Raise
by Zacks Equity Research
GSK's Q2 earnings and revenues top forecasts, with Specialty Medicines and Vaccines driving growth and a raised 2025 outlook boosting shares.
GSKNegative Net Change JNJNegative Net Change VIRNegative Net Change
biotechs earnings medical pharmaceuticals vaccines
Alkermes Q2 Earnings Beat Estimates, Proprietary Drugs Aid Sales
by Zacks Equity Research
ALKS beats second-quarter estimates as proprietary product sales rise 14% y/y, offsetting weaker manufacturing and royalty revenues.
ALKSNegative Net Change CRMDNegative Net Change ARVNNegative Net Change IMCRNegative Net Change
biotechs earnings
Alvotech Gears Up to Report Q2 Earnings: Here's What to Expect
by Zacks Equity Research
ALVO preps for Q2 results as investors eye early U.S. traction for Simlandi and Selarsdi, plus pipeline progress.
RDYNegative Net Change AMGNNegative Net Change TEVAPositive Net Change ALVONegative Net Change
biotechnology biotechs medical pharmaceuticals
NVO Stock Crashes 22% After 2025 View Cut: More Downside Ahead?
by Ahan Chakraborty
Novo Nordisk stock plunges 22% after slashing 2025 sales and profit outlooks, citing weak GLP-1 drugs' uptake and rising competition.
NVOPositive Net Change LLYNegative Net Change VKTXNegative Net Change
biotechnology biotechs medical pharmaceuticals
3 Genomics Stocks Worth Adding to Your Portfolio in 2025
by Ekta Bagri
CRISPR-based innovators like NTLA, EDIT and PRME are gaining traction as genomics reshapes the future of medicine and biotech
ILMNNegative Net Change BEAMNegative Net Change EDITNegative Net Change NTLANo Net Change PRMENegative Net Change CRSPPositive Net Change
biotechnology biotechs gene-editing gene-therapy genetics genomics medical pharmaceuticals
Amgen Gears Up to Report Q2 Earnings: Will the Beat Streak Continue?
by Zacks Equity Research
AMGN eyes another earnings beat as strong drug volumes offset pricing pressure and biosimilar headwinds.
PFENegative Net Change AMGNNegative Net Change CRMDNegative Net Change DNLINegative Net Change
biotechs
Will Collaboration With Bain Capital Help BMY Advance Its Pipeline?
by Ekta Bagri
Bristol Myers partners with Bain Capital to launch a new autoimmune-focused biotech, out-licensing five key immunology assets.
BMYNegative Net Change MRKNegative Net Change AMGNNegative Net Change
biotechnology biotechs medical pharmaceuticals
INCY's Q2 Earnings & Revenues Beat Estimates on Higher Product Sales
by Zacks Equity Research
Incyte reports better-than-expected second-quarter 2025 results, beating both earnings and revenue estimates, driven by strong Jakafi and Opzelura sales.
NVSNegative Net Change LLYNegative Net Change BAYRYNegative Net Change INCYNegative Net Change
biotechnology biotechs earnings medical pharmaceuticals
EXEL Q2 Earnings Top, Sales Miss on Lower Collaboration Revenues
by Zacks Equity Research
EXEL beats on Q2 earnings but misses revenues as lower collaboration income offsets strong Cabometyx sales growth.
RHHBYNegative Net Change BMYNegative Net Change EXELPositive Net Change
biotechnology biotechs earnings medical pharmaceuticals
Vertex Gears Up to Report Q2 Earnings: Is a Beat in the Cards?
by Zacks Equity Research
VRTX eyes second-quarter growth with surging Trikafta sales. Investors' focus is likely to be on the progress of Casgevy, and Alyftrek and Journavx launches.
VRTXNegative Net Change CRMDNegative Net Change EXASNegative Net Change CRSPPositive Net Change
biotechs
Moderna to Report Q2 Earnings: Is a Beat in Store for the Stock?
by Zacks Equity Research
MRNA's second-quarter results are likely to spotlight a sharp decline in Spikevax sales, RSV uptake and key pipeline milestones.
MRKNegative Net Change MRNANegative Net Change EXASNegative Net Change BNTXNegative Net Change
biotechs earnings medical messenger-rna pharmaceuticals vaccines
Pre-Q2 Earnings: Is AbbVie Stock a Portfolio Must-Have?
by Sundeep Ganoria
ABBV's Q2 results are likely to hinge on Skyrizi and Rinvoq growth as Humira declines, with 2025 set for a strong revenue rebound.
RHHBYNegative Net Change JNJNegative Net Change ABBVNegative Net Change
biotechs earnings-preview medical pharmaceuticals
CRISPR Therapeutics to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
CRSP investors await the company's Q2 results with a focus on Casgevy sales growth and updates on gene-editing pipeline progress.
ALKSNegative Net Change VRTXNegative Net Change EXASNegative Net Change CRSPPositive Net Change
biotechs
Will These 5 Pharma/Biotech Bigwigs Surpass Q2 Earnings Forecasts?
by Ahan Chakraborty
Let's look at five biotech and drug companies, MRK, AZN, BMY, ABBV and MRNA, slated to release their second-quarter 2025 results this week.
AZNNegative Net Change BMYNegative Net Change MRKNegative Net Change MRNANegative Net Change ABBVNegative Net Change
biotechnology biotechs earnings medical oncology-screening pharmaceuticals vaccines
Biogen Gears Up to Report Q2 Earnings: Here's What to Expect
by Zacks Equity Research
Biogen's Q2 results may show MS drug declines partially offset by gains from newer drugs.
BIIBNegative Net Change LLYNegative Net Change SUPNNegative Net Change
biotechs
Should You Buy, Hold, or Sell BMY Stock Ahead of Q2 Earnings?
by Ekta Bagri
BMY gears up for Q2 results as growth drugs partially offset legacy declines, cost cuts kick in and new launches gain traction. We recommend investors to wait and watch for now.
BMYNegative Net Change PFENegative Net Change BNTXNegative Net Change
biotechnology biotechs earnings-preview medical pharmaceuticals
Analyst Coverage Sparks Interest in These 4 Stocks Amid Volatility
by Shrabana Mukherjee
New analyst coverage lifts investor interest in KALA, GHM, ARQ, and HWKN as markets grapple with rising volatility.
GHMNegative Net Change HWKNNegative Net Change KALAPositive Net Change ARQPositive Net Change
biotechs industrial-products